Therapeutic Drug Monitoring and Nephrotoxicity of Teicoplanin Therapy in Chinese Children: A Retrospective Study

References

• Venkatesh MP, Placencia F, Weisman LE. Coagulase-negative staphylococcal infections in the neonate and child: an update. Semin Pediatr Infect Dis. 2006;17(3):120–127. doi:10.1053/j.spid.2006.06.00516934706
   PubMedGoogle Scholar
• Maldonado ME, Acuña M, Álvarez AM, et al. Microorganismos aislados de hemocultivos en niños con cáncer y neutropenia febril de alto riesgo en cinco hospitales de Santiago, Chile, período 2012-2015. Revista Chilena de Infectología. 2018;35(2):140–146. doi:10.4067/s0716-1018201800020014029912251
   PubMed Web of Science ®Google Scholar
• Ramos-Martin V, Paulus S, Siner S, et al. Population pharmacokinetics of teicoplanin in children. Antimicrob Agents Chemother. 2014;58(11):6920–6927. doi:10.1128/AAC.03685-1425224001
   PubMed Web of Science ®Google Scholar
• Spencer CM, Bryson HM. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections. Pharmacoeconomics. 1995;7(4):357–374. doi:10.2165/00019053-199507040-0000910155323
   PubMed Web of Science ®Google Scholar
• Zhou LJ, Gao YQ, Cao W, et al. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections. Infect Drug Resist. 2018;11:29–36. doi:10.2147/IDR.S14696129379306
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–1153.32383061
   PubMed Web of Science ®Google Scholar
• Wang TT, Li N, Hu SS, et al. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections. Int J Clin Pharmacol Ther. 2015;53(05):356–362. doi:10.5414/CP20224725828639
   PubMed Web of Science ®Google Scholar
• Targocid EMC 200mg powder for solution for injection/infusion or oral solution. Available from: https://www.medicines.org.uk/emc/product/2926/smpc. Accessed 296 2020.
   Google Scholar
• Yuan DX. Teicoplanin for infusion. Available from: http://drugs.dxy.cn/drug/82481/detail.htm#4. Accessed 296 2020.
   Google Scholar
• Kim S-H, Kang C-I, Huh K, et al. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Eur J Clin Microbiol Infect Dis. 2019;38(11):2113–2120. doi:10.1007/s10096-019-03652-631372903
   PubMed Web of Science ®Google Scholar
• Barco S, Mesini A, Barbagallo L, et al. A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients. J Pharm Biomed Anal. 2020;186:113273. doi:10.1016/j.jpba.2020.11327332251979
   PubMed Web of Science ®Google Scholar
• Yoshida T, Yoshida S, Okada H, et al. Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients. Pharmazie. 2019;74:120–124.30782263
   PubMed Web of Science ®Google Scholar
• Kato H, Hamada Y, Hagihara M, et al. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15–30 μg/mL serum trough concentration. J Infect Chemother. 2016;22(5):308–313. doi:10.1016/j.jiac.2016.01.01926960579
   PubMed Web of Science ®Google Scholar
• Byrne CJ, Egan S, Fennell JP, et al. Teicoplanin use in adult patients with haematological malignancy: exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity. Int J Antimicrob Agents. 2015;46(4):406–412. doi:10.1016/j.ijantimicag.2015.05.01926228465
   PubMed Web of Science ®Google Scholar
• Ramos-Martin V, Neely MN, McGowan P, et al. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. J Antimicrob Chemother. 2016;71(11):3168–3178. doi:10.1093/jac/dkw29527543654
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhang D, Storme T, et al. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. Br J Clin Pharmacol. 2015;80(5):1197–1207. doi:10.1111/bcp.1271026138279
   PubMed Web of Science ®Google Scholar
• Yamada T, Kubota T, Yonezawa M, et al. Evaluation of teicoplanin trough values after the recommended loading dose in children with associated safety analysis. Pediatr Infect Dis J. 2017;36(4):398–400. doi:10.1097/INF.000000000000145627977550
   PubMed Web of Science ®Google Scholar
• Yamada T, Kubota T, Nakamura M, et al. Evaluation of teicoplanin concentrations and safety analysis in neonates. Int J Antimicrob Agents. 2014;44(5):458–462. doi:10.1016/j.ijantimicag.2014.07.00525218156
   PubMed Web of Science ®Google Scholar
• Strenger V, Hofer N, Rödl S, et al. Age- and gender-related differences in teicoplanin levels in paediatric patients. J Antimicrob Chemother. 2013;68:2318–2323.23702837
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;6:CD007022.
   PubMed Web of Science ®Google Scholar
• Kato‐Hayashi H, Niwa T, Ohata K, et al. Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation. J Clin Pharm Ther. 2019;44(6):888–894. doi:10.1111/jcpt.1301131373043
   PubMed Web of Science ®Google Scholar
• Moffett BS, Goldstein SL. Acute Kidney Injury and Increasing Nephrotoxic-Medication Exposure in Noncritically-Ill Children. Clin J Am Soc Nephrol. 2011;6(4):856–863. doi:10.2215/CJN.0811091021212419
   PubMed Web of Science ®Google Scholar
• Hu S, Pang C, Dong H, et al. Determination of teicoplanin serum concentration in critically ill patients. Chine J Hospital Pharmacy. 2011;31:753–755.
   Google Scholar
• Sánchez A, López-Herce J, Cueto E, et al. Teicoplanin pharmacokinetics in critically ill paediatric patients. J Antimicrob Chemother. 1999;44(3):407–409. doi:10.1093/jac/44.3.40710511412
   PubMed Web of Science ®Google Scholar
• Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract. 2008;109(4):c182–187. doi:10.1159/00014292618802365
   PubMedGoogle Scholar
• Jung J, Lee K, Oh J, et al. Therapeutic drug monitoring of teicoplanin using an LC–MS/MS method: analysis of 421 measurements in a naturalistic clinical setting. J Pharm Biomed Anal. 2019;167:161–165. doi:10.1016/j.jpba.2019.02.00130776754
   PubMed Web of Science ®Google Scholar
• Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans.. Antimicrob Agents Chemother. 1992;36(8):1744. doi:10.1128/AAC.36.8.17441416858
   PubMed Web of Science ®Google Scholar
• Gao LL, Xu H, Ye Q, et al. Population pharmacokinetics and dosage optimization of teicoplanin in children with different renal functions. Front Pharmacol. 2020;11:552. doi:10.3389/fphar.2020.0055232431611
   PubMed Web of Science ®Google Scholar
• Cai J, Liu XF, Ni HQ. Analysis of monitoring results and influencing factors of blood drug concentration of different dosages of teicoplanin. Pharmacy Today. 2020;30:565–568.
   Google Scholar
• Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998;10(2):143–152. doi:10.1016/S0924-8579(98)00025-99716291
   PubMed Web of Science ®Google Scholar
• Feiten HDS, Okumura LM, Martinbiancho JK, et al. Vancomycin-associated nephrotoxicity and risk factors in critically ill children without preexisting renal injury. Pediatr Infect Dis J. 2019;38(9):934–938. doi:10.1097/INF.000000000000239131232892
   PubMed Web of Science ®Google Scholar